Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure
Candesartan
NONMEM
Population Pharmacokinetics
DOI:
10.1111/cts.12842
Publication Date:
2020-07-23T17:52:17Z
AUTHORS (11)
ABSTRACT
Heart failure (HF) causes pathological changes in multiple organs, thus affecting the pharmacokinetics (PK) of drugs. The aim this study was to investigate PK candesartan patients with HF while examining significant covariates and their related impact on estimated clearance using a population (Pop-PK) modeling approach. Data from prospective, multicenter were used. Modeling simulations conducted Nonlinear Mixed-Effects (NONMEM) R software. A total 281 white included develop Pop-PK model. final model developed for apparent oral (CL/F) weight, glomerular filtration rate (eGFR), diabetes, which partly explained its interindividual variability. mean CL/F value 7.6 L/h (1.7-22.6 L/h). Simulations revealed that an important decrease (> 25%) is obtained combination factors retained Considering these factors, more individualized approach dosing should be investigated HF.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (30)
CITATIONS (4)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....